Stay updated with breaking news from Howard Sofen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients with moderate to severe scalp psoriasis treated with tildrakizumab exhibited sustained efficacy through week 52, demonstrating the long-term effectiveness and safety profile of this treatment.
Two-thirds of participants achieved complete disease clearance at week 12, with a median time to complete disease clearance of 8 weeks.
Patients with plaque psoriasis, including in intertriginous areas and genitalia, experienced rapid improvement when treated with tapinarof cream 1%, offering an effective and well-tolerated nonsteroidal option for this condition.
Rapid, substantial improvements seen with gusacitinib for chronic hand eczema Source: Sofen H, et al. Efficacy, patient reported outcomes and safety of gusacitinib (ASN002) in chronic hand eczema: Results of a phase 2b, randomized, double-blind, placebo-controlled study. Presented at: AAD VMX; April 23-25, 2021 (virtual meeting). Disclosures: Healio could not confirm relevant financial disclosures at the time of publication. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an em...
email article More than half of patients with steroid-refractory hand eczema responded quickly to a pan-Janus kinase (JAK) inhibitor in a randomized, placebo-controlled trial. After 16 weeks of treatment, patients treated with the higher of two doses of gusacitinib had a 69.5% reduction in target lesion symptom score (TLSS), as compared with 49% among patients randomized to the lower dose of the drug, and 33.5% of placebo-treated patients. Response to gusacitinib occurred as early as 2 weeks after the start of treatment. The higher dose of the JAK inhibitor led to a 72% improvement in t...